Bendopa, Dopar, Inbrija, Larodopa (levodopa) is a small molecule pharmaceutical. Levodopa was first approved as Bendopa on 1982-01-01. It is used to treat parkinson disease in the USA. It has been approved in Europe to treat parkinson disease. It is known to target G-protein coupled receptor 143 and L-DOPA dioxygenase. Sinemet's patents are valid until 2032-11-16 (FDA).
|Drug Class||Dopamine receptor agonists|